MIST - First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT

Milestone Pharmaceuticals (MIST) pivotal Phase 3 study of etripamil nasal spray for the treatment of patients with paroxysmal supraventricular tachycardia ((PSVT)) is now underway.Etripamil, under development as a nasal spray, is a short-acting calcium channel blocker for patients with paroxysmal supraventricular tachycardia ((PSVT)).500-subject in the RAPID trial will be randomized 1:1 to etripamil or placebo, to maximize the potential treatment effect of etripamil, patients who do not experience symptom relief within 10 minutes of the first study drug administration will be directed to administer a second dose of study drug.The primary endpoint of the RAPID trial and NODE-301 trials will be time to conversion of supraventricular tachycardia ((SVT)) within 30 minutes following initial study drug administration, with a target p-value of less than 0.05 for each trial. Top-line results should be available in late 2021/early 2022.Previously in July, Milestone Pharma provided an update on late stage etripamil study.

For further details see:

First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT